+++
title = "BRAIN Biotech Appoints Johan Jansen-Storbacka to Lead Enzyme Products Division"
date = "2025-09-03T23:20:08Z"
draft = false
summary = "BRAIN Biotech AG has appointed Johan Jansen-Storbacka as Executive Vice President of its enzyme products business, signaling strategic commitment to strengthening its global enzyme and fermentation operations."
description = "BRAIN Biotech appoints Johan Jansen-Storbacka as EVP to lead enzyme products business, strengthening their position in sustainable biotechnology solutions and industrial innovation."
source_link = "https://www.newmediawire.com/news/brain-biotech-ag-appoints-johan-jansen-storbacka-as-executive-vice-president-of-the-brainbiocatalysts-enzyme-products-business-7082367"
enclosure = "https://cdn.newsramp.app/newmediawire/newsimage/c806f8bcc5e35f0560852ee131381bd5.gif"
article_id = 195055
feed_item_id = 19914
qrcode = "https://cdn.newsramp.app/newmediawire/qrcode/259/3/yarn7ebo.webp"
source = "NewMediaWire"
+++

<p>BRAIN Biotech AG has appointed Johan Jansen-Storbacka as Executive Vice President of the BRAINBiocatalysts' enzyme products business, effective September 1, 2025. Jansen-Storbacka succeeds Rod Sears-Black, who retired earlier this year, with CEO Adriaan Moelker temporarily overseeing the role during the interim period.</p><p>With over 20 years of experience in biotechnology, Jansen-Storbacka brings extensive expertise in enzyme applications across industrial processes, animal nutrition, and home care sectors. He holds both an M.Sc. in Engineering and Management and an MBA, providing him with the technical and business acumen required for this leadership position.</p><p>In his new role, Jansen-Storbacka will oversee approximately 140 employees and manage fermentation facilities in the UK along with production sites in continental Europe and the United States. The company operates multiple facilities globally, including production sites detailed at <a href="https://www.biocatalysts.com/" rel="nofollow" target="_blank">https://www.biocatalysts.com/</a>.</p><p>Adriaan Moelker, CEO of BRAIN Biotech, emphasized the significance of this appointment, stating that Jansen-Storbacka's broad industry background will be valuable in serving diverse end markets. His international experience and proven leadership skills position him as an ideal fit for leading the enzyme products business segment.</p><p>BRAIN Biotech Group specializes in researching, developing, and producing specialty enzymes for the food and life sciences industries, while also developing microbial production strains and scalable bioprocesses for economic protein production. More information about the company's operations can be found at <a href="https://www.brain-biotech-group.com/" rel="nofollow" target="_blank">https://www.brain-biotech-group.com/</a>.</p><p>The appointment comes as BRAIN Biotech continues to expand its global footprint and enhance its position in the biologization of industry. The company reported revenue of â‚¬54.6 million in the 2023/24 fiscal year and employs approximately 300 people worldwide. This leadership change represents a strategic move to drive growth and innovation in the rapidly evolving biotechnology sector, particularly in enzyme applications that support more sustainable products and efficient industrial processes.</p>